S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
Best Bear Market Funds: Top 3 Investment Options to Consider
How and When to Roll Your Options Positions?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
Best Bear Market Funds: Top 3 Investment Options to Consider
How and When to Roll Your Options Positions?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
Best Bear Market Funds: Top 3 Investment Options to Consider
How and When to Roll Your Options Positions?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
Best Bear Market Funds: Top 3 Investment Options to Consider
How and When to Roll Your Options Positions?
NASDAQ:ITOS

iTeos Therapeutics (ITOS) Stock Price, News & Analysis

$13.17
+0.82 (+6.64%)
(As of 03/27/2024 ET)
Today's Range
$12.56
$13.42
50-Day Range
$9.89
$13.17
52-Week Range
$8.20
$18.24
Volume
595,613 shs
Average Volume
249,602 shs
Market Capitalization
$472.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.33

iTeos Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
130.3% Upside
$30.33 Price Target
Short Interest
Bearish
7.05% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.17mentions of iTeos Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($4.76) to ($6.19) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.86 out of 5 stars

Medical Sector

623rd out of 939 stocks

Biological Products, Except Diagnostic Industry

105th out of 156 stocks

ITOS stock logo

About iTeos Therapeutics Stock (NASDAQ:ITOS)

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

ITOS Stock Price History

ITOS Stock News Headlines

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Short Interest Update
Did you make $29,000 two days with AI options trades?
What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:
ITOS Oct 2024 17.000 call
ITOS Oct 2024 12.000 call
ITOS Mar 2024 4.000 put
Did you make $29,000 two days with AI options trades?
What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:
ITOS Mar 2024 11.000 call
iTeos Therapeutics (NASDAQ: ITOS)
See More Headlines
Receive ITOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iTeos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/06/2024
Today
3/28/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ITOS
Fax
N/A
Employees
157
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$30.33
High Stock Price Target
$44.00
Low Stock Price Target
$18.00
Potential Upside/Downside
+130.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-112,640,000.00
Pretax Margin
-865.66%

Debt

Sales & Book Value

Annual Sales
$12.60 million
Book Value
$16.08 per share

Miscellaneous

Free Float
32,187,000
Market Cap
$472.01 million
Optionable
Optionable
Beta
1.15
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

ITOS Stock Analysis - Frequently Asked Questions

Should I buy or sell iTeos Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for iTeos Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ITOS shares.
View ITOS analyst ratings
or view top-rated stocks.

What is iTeos Therapeutics' stock price target for 2024?

3 analysts have issued twelve-month price targets for iTeos Therapeutics' stock. Their ITOS share price targets range from $18.00 to $44.00. On average, they expect the company's stock price to reach $30.33 in the next year. This suggests a possible upside of 130.3% from the stock's current price.
View analysts price targets for ITOS
or view top-rated stocks among Wall Street analysts.

How have ITOS shares performed in 2024?

iTeos Therapeutics' stock was trading at $10.95 on January 1st, 2024. Since then, ITOS shares have increased by 20.3% and is now trading at $13.17.
View the best growth stocks for 2024 here
.

Are investors shorting iTeos Therapeutics?

iTeos Therapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 2,010,000 shares, an increase of 11.7% from the February 29th total of 1,800,000 shares. Based on an average daily volume of 256,400 shares, the short-interest ratio is presently 7.8 days. Approximately 7.1% of the shares of the stock are short sold.
View iTeos Therapeutics' Short Interest
.

When is iTeos Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our ITOS earnings forecast
.

How were iTeos Therapeutics' earnings last quarter?

iTeos Therapeutics, Inc. (NASDAQ:ITOS) posted its quarterly earnings results on Wednesday, March, 6th. The company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($1.03) by $0.18.

What ETFs hold iTeos Therapeutics' stock?

ETFs with the largest weight of iTeos Therapeutics (NASDAQ:ITOS) stock in their portfolio include Invesco S&P SmallCap 600 Pure Growth ETF (RZG) and Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What other stocks do shareholders of iTeos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iTeos Therapeutics investors own include Advanced Micro Devices (AMD), GW Pharmaceuticals (GWPH), Trevena (TRVN), Blink Charging (BLNK), Chegg (CHGG), Centene (CNC), Datadog (DDOG), Global Blood Therapeutics (GBT) and Genocea Biosciences (GNCA).

When did iTeos Therapeutics IPO?

iTeos Therapeutics (ITOS) raised $151 million in an IPO on Friday, July 24th 2020. The company issued 8,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, SVB Leerink and Piper Sandler served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are iTeos Therapeutics' major shareholders?

iTeos Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.17%), Vanguard Group Inc. (4.16%), Dimensional Fund Advisors LP (2.16%), Goldman Sachs Group Inc. (2.07%), Goldman Sachs Group Inc. (2.07%) and Barclays PLC (0.87%). Insiders that own company stock include Aaron I Davis, Ansbert Gadicke, Bioventures 2014 LP Mpm, Bioventures 2018 LP Mpm, Boxer Capital, Llc, David Hallal, Detlev Biniszkiewicz, Joanne Jenkins Lager, Les B Korsh, Matthew Gall, Michel Detheux and Yvonne Mcgrath.
View institutional ownership trends
.

How do I buy shares of iTeos Therapeutics?

Shares of ITOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ITOS) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners